- Company
- Trelegy 200 Ellipta may be prescribed at tertiary hospitals
- by Eo, Yun-Ho Jun 25, 2024 05:46am
- The double dose Trelegy Ellipta, which received approval in Korea for asthma, not COPD, may now be prescribed at general hospitals in Korea. According to industry sources, GSK Korea's Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) has passed the drug committees (DCs) of the Big 5 tertiary hospitals in Korea, including Sam
- Company
- 'Camzyos' receives DREC’s reconsideration decision
- by Eo, Yun-Ho Jun 25, 2024 05:46am
- The final decision was not reached on the first attempt. The path to getting 'Camzyos,' the first novel drug for obstructive hypertrophic cardiomyopathy (oHCM), listed for reimbursement seems to be challenging. According to the industry sources, BMS Korea’s Camzyos (mavacamten), a novel drug used to treat obstructive hypertrophic cardio
- Policy
- LG Chem and Samsung Bioepis's biosimilars are reimbursed
- by Lee, Tak-Sun Jun 25, 2024 05:46am
- LG Chem and Samsung Bioepis’ biosimilar products will be listed for reimbursement in July. LG Chem is launching a biosimilar of the autoimmune disease treatment Humira, and Samsung Bioepis is launching a biosimilar of Stelara. Both are aiming to list at the lowest price to compete with their respective original products. According to i
- Policy
- Combinatory drugs with linagliptin+dapagliflozin
- by Lee, Tak-Sun Jun 25, 2024 05:46am
- Following the patent expiration of DPP-4 inhibitor Trajenta (linagliptin), combinatory drugs containing linagliptin have been released. Next month, a combinatory drug containing linagliptin combined with SGLT-2 inhibitory dapagliflozin will enter the market. It is a combinatory drug with a new combination being introduced in South Korea. Acco
- Opinion
- [Reporter's View] No more exemptions, just deferrals
- by Eo, Yun-Ho Jun 24, 2024 05:47am
- The Korean government has set out to fix the pharmacoeconomic evaluation exemption system. Although the authorities coined it as an “improvement,” the direction seems to be near a “reduction.” A report on a study commissioned by the Health Insurance Review and Assessment Service was released at the end of last year. The study, titled
- Policy
- Will GMP One-strike-out be loosened?...MFDS, 'negative'
- by Lee, Hye-Kyung Jun 24, 2024 05:47am
- While pharmaceutical companies advocate for loosening the 'Cancellation of the GMP compliance decision' act, the Ministry of Food and Drug Safety (MFDS) says it will start a discussion once it receives an official submission of opinions. This is in response to biopharmaceutical companies’ submission of a statement last month regarding t
- Company
- K-Bios make bid into pancreatic cancer treatment environment
- by Son, Hyung-Min Jun 24, 2024 05:47am
- The domestic pharmaceutical and bio-industry has made a bid into the development of new drugs for pancreatic cancer through the use of combination therapy. Despite the development of various treatments to date, the five-year survival rate of pancreatic cancer has remained the lowest among the top 10 cancers, at 12.6%. Pancreatic cancer is diffic
- Policy
- Price of BI’s diabetes drug Trajenta is cut 30% from July
- by Lee, Tak-Sun Jun 24, 2024 05:46am
- Price of Boehringer Ingelheim’s flagship diabetes drugs ‘Trajenta’ and ‘Jardiance’ will both be cut in July. Trajenta will receive an ex officio price cut due to the entry of its generic while Jardiance will see a price cut after completing price-volume agreement (PVA) negotiations. According to industry sources on the 21st, the i
- Company
- Pfizer reapplies for reimb listing of Vyndamax in Korea
- by Eo, Yun-Ho Jun 21, 2024 05:47am
- ‘Vyndamax,’ a new drug for transthyretin&160;amyloid cardiomyopathy (ATTR-CM), is again attempting reimbursement listing in Korea. According to industry sources, Pfizer Korea had recently submitted an application for the insurance reimbursement of Vyndamax, its new drug for transthyretin amyloid cardiomyopathy (ATTR-CM). Vyndamax f
- Policy
- Low-dose 'nicergoline' is increasingly becoming available
- by Lee, Hye-Kyung Jun 21, 2024 05:47am
- Old drugs containing the active ingredient 'nicergoline' are on the rise for substituting 'choline alfoscerate,' which is under reassessment of clinical and reimbursement. The lower doses are also being approved. Previously, companies mostly received approvals for items containing 30 mg doses, which obtained indications for the first-l
